
Missak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Your AI-Trained Oncology Knowledge Connection!


Missak Haigentz Jr., MD, discusses the importance of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center, medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the impact that immunotherapy has had on the treatment of patients with head and neck cancer.

Published: September 20th 2018 | Updated:

Published: November 17th 2018 | Updated: